ADAR1 Capital Management LLC Cuts Stake in Zura Bio Limited (NASDAQ:ZURA)

ADAR1 Capital Management LLC decreased its stake in Zura Bio Limited (NASDAQ:ZURA) by 44.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,077,251 shares of the company’s stock after selling 1,693,398 shares during the period. Zura Bio makes up 1.0% of ADAR1 Capital Management LLC’s portfolio, making the stock its 22nd biggest position. ADAR1 Capital Management LLC owned 3.18% of Zura Bio worth $5,193,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the stock. American Century Companies Inc. purchased a new position in Zura Bio in the 4th quarter worth approximately $27,000. Prudential Financial Inc. acquired a new position in Zura Bio in the 4th quarter worth $28,000. SG Americas Securities LLC boosted its position in Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after buying an additional 7,828 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Zura Bio by 68.6% during the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after acquiring an additional 9,379 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Zura Bio during the third quarter worth about $71,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Stock Down 5.1 %

Shares of NASDAQ:ZURA opened at $1.03 on Monday. The company has a market cap of $67.25 million, a PE ratio of -1.94 and a beta of 0.08. Zura Bio Limited has a fifty-two week low of $0.97 and a fifty-two week high of $6.35. The firm has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $2.63.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. As a group, research analysts forecast that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright dropped their price target on shares of Zura Bio from $5.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday. Oppenheimer reiterated an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital dropped their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Finally, Guggenheim reaffirmed a “buy” rating and set a $15.00 price target on shares of Zura Bio in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.